Last mentioned: Mar 9, 2026
Pipeline Expansion
Expected utilization of funds to advance additional candidates from the OPERA platform.
Clinical Milestone Expected
Anticipated progress updates on the KRRO-110 Phase 1/2 clinical trial for AATD.
Private Placement Announced
Korro Bio announces the closing of an $85 million oversubscribed private placement.
Korro Bio (NASDAQ: KRRO) has successfully closed an $85 million private placement, signaling strong investor confidence in its proprietary RNA editing platform. The capital infusion is earmarked for the clinical advancement of its lead candidate, KRRO-110, and the expansion of its OPERA platform.
This page surfaces every story mentioning KRRO-110 across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where KRRO-110 was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |